MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) announced today that it has delivered the first formulation under its worldwide license agreement with Covidien focusing on the exclusive development of four products utilizing Depomed’s Acuform® gastric retentive drug delivery technology. The delivery of the first formulation to Covidien triggers a $500,000 milestone payment.
